Bispecific Antibodies Transform Hemophilia Care
Bispecific antibodies are revolutionizing hemophilia A treatment, providing new possibilities where traditional therapies face limitations. Through the innovative mechanism of mimicking factor VIII, these therapies offer less invasive options and reduce inhibitor risks. Emicizumab, a key player, exemplifies this advancement, aiming for global accessibility and enhanced patient outcomes. Understand the transformative impact within hemophilia management. […]
3 minute read